<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35419092</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1844-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of medicine and life</Title><ISOAbbreviation>J Med Life</ISOAbbreviation></Journal><ArticleTitle>Diet, fibers, and probiotics for irritable bowel syndrome.</ArticleTitle><Pagination><StartPage>174</StartPage><EndPage>179</EndPage><MedlinePgn>174-179</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.25122/jml-2022-0028</ELocationID><Abstract><AbstractText>Many aspects make irritable bowel syndrome (IBS) challenging for both patients and physicians. The unclear pathogenesis with many pathways to be explored, bothering symptoms that affect the quality of life, and many subtypes of the condition are only a few reasons that make IBS difficult to control and obtain satisfactory results. Treatment options start with general advice for lifestyle, continue with non-pharmaceutical treatments, and finally touch classic treatments. In this review, pharmaceutical treatment options are not accounted for. Consensus groups and meta-analyses have concluded guidelines that overall are the same, with variations in the strength of recommendations and some cultural and geographical particularities. Dietary interventions, probiotics, and fibers can be seen as non-pharmaceutical treatments that coexist in various protocols because of the relevant evidence regarding their efficacy in treating IBS symptoms.</AbstractText><CopyrightInformation>&#xa9;2022 JOURNAL of MEDICINE and LIFE.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Adelina Nicoleta</ForeName><Initials>AN</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nursing, Faculty of Natural and Human Sciences, Fan S. Noli University, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galica</LastName><ForeName>Reitano</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Regional Hospital Kor&#xe7;e, Kor&#xe7;e, Albania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dumitra&#x219;cu</LastName><ForeName>Dan Lucian</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>2 Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Romania</Country><MedlineTA>J Med Life</MedlineTA><NlmUniqueID>101477617</NlmUniqueID><ISSNLinking>1844-122X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004187">Disaccharides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009005">Monosaccharides</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004187" MajorTopicYN="N">Disaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005285" MajorTopicYN="N">Fermentation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009005" MajorTopicYN="N">Monosaccharides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FGID &#x2013; functional gastrointestinal disorders</Keyword><Keyword MajorTopicYN="N">FODMAP</Keyword><Keyword MajorTopicYN="N">FODMAP &#x2013; fermentable oligosaccharides, disaccharides, monosaccharides, and polyols</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; C irritable bowel syndrome subtype with constipation</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; D irritable bowel syndrome subtype with diarrhea</Keyword><Keyword MajorTopicYN="N">IBS &#x2013; irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">LFD &#x2013; low FODMAP diet</Keyword><Keyword MajorTopicYN="N">NICE/mNICE &#x2013; National Institute for Health and Care Excellence/modified diet</Keyword><Keyword MajorTopicYN="N">gut microbiota</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">non-pharmacological therapy</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35419092</ArticleId><ArticleId IdType="pmc">PMC8999090</ArticleId><ArticleId IdType="doi">10.25122/jml-2022-0028</ArticleId><ArticleId IdType="pii">JMedLife-15-174</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drossman DA. Functional gastrointestinal disorder and the Rome IV process. Functional gastrointestinal disorders. In: Drossman DA, Chang L, Chey WD, et al., editors. Disorders of brain-gut interaction. 4th. Vol. 1. Raleigh, NC: Rome Foundation; 2016. pp. 1&#x2013;32.</Citation></Reference><Reference><Citation>Enck P, Aziz Q, Barbara G, Farmer AD, et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016;2:16014. doi: 10.1038/nrdp.2016.14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.14</ArticleId><ArticleId IdType="pmc">PMC5001845</ArticleId><ArticleId IdType="pubmed">27159638</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Dumitrascu DL, Fukudo S, Gerson C, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. 2017;66(6):1075&#x2013;1082. doi: 10.1136/gutjnl-2015-311240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311240</ArticleId><ArticleId IdType="pubmed">26818616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712&#x2013;721.e4. doi: 10.1016/j.cgh.2012.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.02.029</ArticleId><ArticleId IdType="pubmed">22426087</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99&#x2013;114.e3. doi: 10.1053/j.gastro.2020.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId><ArticleId IdType="pubmed">32294476</ArticleId></ArticleIdList></Reference><Reference><Citation>Palsson OS, Whitehead W, T&#xf6;rnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020;158(5):1262&#x2013;1273.e3. doi: 10.1053/j.gastro.2019.12.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2019.12.021</ArticleId><ArticleId IdType="pubmed">31917991</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P, Staller K, Barshop K, Dai E, et al. Patients with irritable bowel syndrome-diarrhea have lower disease-specific quality of life than irritable bowel syndrome-constipation. World J Gastroenterol. 2015;21(26):8103&#x2013;8109. doi: 10.3748/wjg.v21.i26.8103.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i26.8103</ArticleId><ArticleId IdType="pmc">PMC4499353</ArticleId><ArticleId IdType="pubmed">26185382</ArticleId></ArticleIdList></Reference><Reference><Citation>Drossman DA, Chang L, Schneck S, Blackman C, et al. A focus group assessment of patient perspectives on irritable bowel syndrome and illness severity. Dig Dis Sci. 2009;54(7):1532&#x2013;1541. doi: 10.1007/s10620-009-0792-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-009-0792-6</ArticleId><ArticleId IdType="pubmed">19337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Ford AC. Global burden of irritable bowel syndrome: trends, predictions and risk factors. Nat Rev Gastroenterol Hepatol. 2020;17(8):473&#x2013;486. doi: 10.1038/s41575-020-0286-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Surdea-Blaga T, Cozma-Petrut A, Dumitra&#x15f;cu DL. Dietary interventions and irritable bowel syndrome &#x2013; what really works?. Curr Opin Gastroenterol. 2021;37(2):152&#x2013;157. doi: 10.1097/MOG.0000000000000706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOG.0000000000000706</ArticleId><ArticleId IdType="pubmed">33332914</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozma-Petru&#x163; A, Loghin F, Miere D, Dumitra&#x15f;cu DL. Diet in irritable bowel syndrome: What to recommend, not what to forbid to patients!. World J Gastroenterol. 2017;23(21):3771&#x2013;3783. doi: 10.3748/wjg.v23.i21.3771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i21.3771</ArticleId><ArticleId IdType="pmc">PMC5467063</ArticleId><ArticleId IdType="pubmed">28638217</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Jakobsson Ung E, Sadik R, Ringstr&#xf6;m G. Experiences of the effects of physical activity in persons with irritable bowel syndrome (IBS): a qualitative content analysis. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1194&#x2013;1200. doi: 10.1080/00365521.2018.1519596.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365521.2018.1519596</ArticleId><ArticleId IdType="pubmed">30472905</ArticleId></ArticleIdList></Reference><Reference><Citation>Johannesson E, Ringstr&#xf6;m G, Abrahamsson H, Sadik R. Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects. World J Gastroenterol. 2015 Jan 14;21(2):600&#x2013;8. doi: 10.3748/wjg.v21.i2.600.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v21.i2.600</ArticleId><ArticleId IdType="pmc">PMC4294172</ArticleId><ArticleId IdType="pubmed">25593485</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Hausken T. Diet in Irritable Bowel Syndrome (IBS): Interaction with Gut Microbiota and Gut Hormones. Nutrients. 2019;11(8):1824. doi: 10.3390/nu11081824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu11081824</ArticleId><ArticleId IdType="pmc">PMC6723613</ArticleId><ArticleId IdType="pubmed">31394793</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh K, Reed DE, Schneider T, Dang F, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomised controlled trial. Gut. 2017 Jul;66(7):1241&#x2013;1251. doi: 10.1136/gutjnl-2015-311339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2015-311339</ArticleId><ArticleId IdType="pubmed">26976734</ArticleId></ArticleIdList></Reference><Reference><Citation>Eswaran SL, Chey WD, Han-Markey T, Ball S, Jackson K. A Randomized Controlled Trial Comparing the Low FODMAP Diet vs. Modified NICE Guidelines in US Adults with IBS-D. Am J Gastroenterol. 2016;111(12):1824&#x2013;1832. doi: 10.1038/ajg.2016.434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.434</ArticleId><ArticleId IdType="pubmed">27725652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson PR, Halmos EP, Muir JG. Review article: FODMAPS, prebiotics and gut health-the FODMAP hypothesis revisited. Aliment Pharmacol Ther. 2020;52:233&#x2013;246. doi: 10.1111/apt.15818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15818</ArticleId><ArticleId IdType="pubmed">32562590</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xf6;hn L, St&#xf6;rsrud S, Liljebo T, Collin L, et al. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015;149(6):1399&#x2013;1407.e2. doi: 10.1053/j.gastro.2015.07.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2015.07.054</ArticleId><ArticleId IdType="pubmed">26255043</ArticleId></ArticleIdList></Reference><Reference><Citation>Staudacher HM, Lomer MC, Anderson JL, Barrett JS, et al. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142(8):1510&#x2013;1518. doi: 10.3945/jn.112.159285.</Citation><ArticleIdList><ArticleId IdType="doi">10.3945/jn.112.159285</ArticleId><ArticleId IdType="pubmed">22739368</ArticleId></ArticleIdList></Reference><Reference><Citation>Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014;146(1):67&#x2013;75.e5. doi: 10.1053/j.gastro.2013.09.046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2013.09.046</ArticleId><ArticleId IdType="pubmed">24076059</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitrascu DL, Baban A, Bancila I, Barboi O, et al. Romanian Guidelines for Nonpharmacological Therapy of IBS. J Gastrointestin Liver Dis. 2021;30(2):291&#x2013;306. doi: 10.15403/jgld-3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.15403/jgld-3581</ArticleId><ArticleId IdType="pubmed">33951120</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira AI, Garrido M, Castro-Po&#xe7;as F. Irritable Bowel Syndrome: News from an Old Disorder. GE Port J Gastroenterol. 2020;27(4):255&#x2013;268. doi: 10.1159/000503757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000503757</ArticleId><ArticleId IdType="pmc">PMC7383263</ArticleId><ArticleId IdType="pubmed">32775547</ArticleId></ArticleIdList></Reference><Reference><Citation>Gravina AG, Dallio M, Romeo M, Di Somm A, et al. Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation. Nutrients. 2020;12(4):928. doi: 10.3390/nu12040928.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12040928</ArticleId><ArticleId IdType="pmc">PMC7231245</ArticleId><ArticleId IdType="pubmed">32230832</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Keeffe M, Jansen C, Martin L, Williams M, et al. Long-term impact of the low-FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome. Neurogastroenterol Motil. 2018;30(1) doi: 10.1111/nmo.13154. doi: 10.1111/nmo.13154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="doi">10.1111/nmo.13154</ArticleId><ArticleId IdType="pubmed">28707437</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpato E, Auricchio R, Penagini F, Campanozzi A, et al. Efficacy of the gluten free diet in the management of functional gastrointestinal disorders: a systematic review on behalf of the Italian Society of Paediatrics. Ital J Pediatr. 2019;45(1):9. doi: 10.1186/s13052-019-0606-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13052-019-0606-1</ArticleId><ArticleId IdType="pmc">PMC6329096</ArticleId><ArticleId IdType="pubmed">30635010</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Deng Y, Chu H, Cong Y, et al. Prevalence and presentation of lactose intolerance and effects on dairy product intake in healthy subjects and patients with irritable bowel syndrome. Clin Gastroenterol Hepatol. 2013;11:262&#x2013;268.e1. doi: 10.1016/j.cgh.2012.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2012.11.034</ArticleId><ArticleId IdType="pubmed">23246646</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta D, Ghoshal UC, Misra A, Misra A, et al. Lactose intolerance in patients with irritable bowel syndrome from northern India: a case-control study. J Gastroenterol Hepatol. 2007;22:2261&#x2013;2265. doi: 10.1111/j.1440-1746.2007.04986.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1440-1746.2007.04986.x</ArticleId><ArticleId IdType="pubmed">17559357</ArticleId></ArticleIdList></Reference><Reference><Citation>Varju P, Gede N, Szakacs Z, Hegyi P, et al. Lactose intolerance but not lactose maldigestion is more frequent in patients with irritable bowel syndrome than in healthy controls: A meta-analysis. Neurogastroenterol Motil. 2019;31:e13527. doi: 10.1111/nmo.13527.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nmo.13527</ArticleId><ArticleId IdType="pmc">PMC7379306</ArticleId><ArticleId IdType="pubmed">30560578</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Lacy BE, Talley NJ. Irritable Bowel Syndrome. N Engl J Med. 2017;376:2566&#x2013;2578. doi: 10.1056/NEJMra1607547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1607547</ArticleId><ArticleId IdType="pubmed">28657875</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagarajan N, Morden A, Bischof D, King EA, et al. The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2015;27:1002&#x2013;1010. doi: 10.1097/MEG.0000000000000425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000425</ArticleId><ArticleId IdType="pubmed">26148247</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Quigley EM, Lacy BE, Lembo AJ, et al. The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109(9):1367&#x2013;1374. doi: 10.1038/ajg.2014.195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2014.195</ArticleId><ArticleId IdType="pubmed">25070054</ArticleId></ArticleIdList></Reference><Reference><Citation>McRorie JW. Evidence-Based Approach to Fiber Supplementsand Clinically Meaningful Health Benefits, Part 1: What to Look for and How to Recommend an Effective Fiber Therapy. Nutr Today. 2015;50:82&#x2013;89. doi: 10.1097/NT.0000000000000082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NT.0000000000000082</ArticleId><ArticleId IdType="pmc">PMC4415962</ArticleId><ArticleId IdType="pubmed">25972618</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P, Andrews CN, MacQueen G, Korownyk C, et al. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J Can Assoc Gastroenterol. 2019 Apr;2(1):6&#x2013;29. doi: 10.1093/jcag/gwy071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care?Randomised placebo controlled trial. BMJ. 2009;339:b3154. doi: 10.1136/bmj.b3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b3154</ArticleId><ArticleId IdType="pmc">PMC3272664</ArticleId><ArticleId IdType="pubmed">19713235</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh B. Psyllium as therapeutic and drug delivery agent. Int J Pharm. 2007;334(1-2):1&#x2013;14. doi: 10.1016/j.ijpharm.2007.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijpharm.2007.01.028</ArticleId><ArticleId IdType="pubmed">17329047</ArticleId></ArticleIdList></Reference><Reference><Citation>Muir J. An Overview of Fiber and Fiber Supplements for Irritable Bowel Syndrome. Gastroenterol Hepatol (N Y) 2019;15:387&#x2013;389.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6676347</ArticleId><ArticleId IdType="pubmed">31391809</ArticleId></ArticleIdList></Reference><Reference><Citation>Toskes PP, Connery KL, Ritchey TW. Calcium polycarbophil compared with placebo in irritable bowel syndrome. Aliment Pharmacol Ther. 1993;7(1):87&#x2013;92. doi: 10.1111/j.1365-2036.1993.tb00074.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.1993.tb00074.x</ArticleId><ArticleId IdType="pubmed">8439642</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Bowyer RK, Leach H, Gulia P, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016 Oct;29(5):549&#x2013;75. doi: 10.1111/jhn.12385.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12385</ArticleId><ArticleId IdType="pubmed">27272325</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson GR, Hutkins R, Sanders ME, Prescott SL, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491&#x2013;502. doi: 10.1038/nrgastro.2017.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2017.75</ArticleId><ArticleId IdType="pubmed">28611480</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014 Aug;11(8):506&#x2013;14. doi: 10.1038/nrgastro.2014.66.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId><ArticleId IdType="pubmed">24912386</ArticleId></ArticleIdList></Reference><Reference><Citation>Distrutti E, Monaldi L, Ricci P, Fiorucci S. Gut microbiota role in irritable bowel syndrome: New therapeutic strategies. World J Gastroenterol. 2016;22(7):2219&#x2013;2241. doi: 10.3748/wjg.v22.i7.2219.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i7.2219</ArticleId><ArticleId IdType="pmc">PMC4734998</ArticleId><ArticleId IdType="pubmed">26900286</ArticleId></ArticleIdList></Reference><Reference><Citation>Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823&#x2013;1836. doi: 10.1042/BCJ20160510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BCJ20160510</ArticleId><ArticleId IdType="pmc">PMC5433529</ArticleId><ArticleId IdType="pubmed">28512250</ArticleId></ArticleIdList></Reference><Reference><Citation>Mari A, Abu Bake F, Mahamid M, Sbeit W, Khoury T. The Evolving Role of Gut Microbiota in the Management of Irritable Bowel Syndrome: An Overview of the Current Knowledge. J Clin Med. 2020;9(3):685. doi: 10.3390/jcm9030685.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9030685</ArticleId><ArticleId IdType="pmc">PMC7141230</ArticleId><ArticleId IdType="pubmed">32143424</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodi&#xf1;o-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-Garc&#xed;a R, Santos J. A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies. Adv Ther. 2018;35(3):289&#x2013;310. doi: 10.1007/s12325-018-0673-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12325-018-0673-5</ArticleId><ArticleId IdType="pmc">PMC5859043</ArticleId><ArticleId IdType="pubmed">29498019</ArticleId></ArticleIdList></Reference><Reference><Citation>McKenzie YA, Thompson J, Gulia P, Lomer MC, (IBS Dietetic Guideline Review Group on behalf of Gastroenterology Specialist Group of the British Dietetic Association) British Dietetic Association systematic review of systematic reviews and evidence-based practice guidelines for the use of probiotics in the management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):576&#x2013;592. doi: 10.1111/jhn.12386.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jhn.12386</ArticleId><ArticleId IdType="pubmed">27265510</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018 Nov;48(10):1044&#x2013;1060. doi: 10.1111/apt.15001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S, Okumura T, Inamori M, Okuyama Y, et al. Evidence-based clinical practice guidelines for irritable bowel syndrome 2020. J Gastroenterol. 2021;56(3):193&#x2013;217. doi: 10.1007/s00535-020-01746-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Herndon CC, Wang YP, Lu CL. Targeting the gut microbiota for the treatment of irritable bowel syndrome. Kaohsiung J Med Sci. 2020;36(3):160&#x2013;170. doi: 10.1002/kjm2.12154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/kjm2.12154</ArticleId><ArticleId IdType="pmc">PMC11896346</ArticleId><ArticleId IdType="pubmed">31782606</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan F, Ni H, Asche CV, Kim M, et al. Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis. Curr Med Res Opin. 2017;33(7):1191&#x2013;1197. doi: 10.1080/03007995.2017.1292230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03007995.2017.1292230</ArticleId><ArticleId IdType="pubmed">28166427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cayzeele-Decherf A, Pelerin F, Leuillet S, Douillard B, et al. Saccharomyces cerevisiae CNCM I-3856 in irritable bowel syndrome: An individual subject meta-analysis. World J Gastroenterol. 2017;23(2):336&#x2013;344. doi: 10.3748/wjg.v23.i2.336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v23.i2.336</ArticleId><ArticleId IdType="pmc">PMC5236513</ArticleId><ArticleId IdType="pubmed">28127207</ArticleId></ArticleIdList></Reference><Reference><Citation>Fikree A, Byrne P. Management of functional gastrointestinal disorders. Clin Med (Lond). 2021;21(1):44&#x2013;52. doi: 10.7861/clinmed.2020-0980.</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0980</ArticleId><ArticleId IdType="pmc">PMC7850201</ArticleId><ArticleId IdType="pubmed">33479067</ArticleId></ArticleIdList></Reference><Reference><Citation>Doron S, Snydman DR. Risk and safety of probiotics. Clin Infect Dis. 2015;60(Suppl 2(Suppl 2)):S129&#x2013;S134. doi: 10.1093/cid/civ085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ085</ArticleId><ArticleId IdType="pmc">PMC4490230</ArticleId><ArticleId IdType="pubmed">25922398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil. 2011;17(3):252&#x2013;266. doi: 10.5056/jnm.2011.17.3.252.</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm.2011.17.3.252</ArticleId><ArticleId IdType="pmc">PMC3155061</ArticleId><ArticleId IdType="pubmed">21860817</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22314561</PMID><DateCompleted><Year>2012</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1899-1505</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>6</Issue><PubDate><Year>2011</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of physiology and pharmacology : an official journal of the Polish Physiological Society</Title><ISOAbbreviation>J Physiol Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options.</ArticleTitle><Pagination><StartPage>591</StartPage><EndPage>599</EndPage><MedlinePgn>591-9</MedlinePgn></Pagination><Abstract><AbstractText>Stress, which is defined as an acute threat to homeostasis, shows both short- and long-term effects on the functions of the gastrointestinal tract. Exposure to stress results in alterations of the brain-gut interactions ("brain-gut axis") ultimately leading to the development of a broad array of gastrointestinal disorders including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and other functional gastrointestinal diseases, food antigen-related adverse responses, peptic ulcer and gastroesophageal reflux disease (GERD). The major effects of stress on gut physiology include: 1) alterations in gastrointestinal motility; 2) increase in visceral perception; 3) changes in gastrointestinal secretion; 4) increase in intestinal permeability; 5) negative effects on regenerative capacity of gastrointestinal mucosa and mucosal blood flow; and 6) negative effects on intestinal microbiota. Mast cells (MC) are important effectors of brain-gut axis that translate the stress signals into the release of a wide range of neurotransmitters and proinflammatory cytokines, which may profoundly affect the gastrointestinal physiology. IBS represents the most important gastrointestinal disorder in humans, and is characterized by chronic or recurrent pain associated with altered bowel motility. The diagnostic testing for IBS patients include routine blood tests, stool tests, celiac disease serology, abdominal sonography, breath testing to rule out carbohydrate (lactose, fructose, etc.) intolerance and small intestinal bacterial overgrowth. Colonoscopy is recommended if alarming symptoms are present or to obtain colonic biopsies especially in patients with diarrhoea predominant IBS. The management of IBS is based on a multifactorial approach and includes pharmacotherapy targeted against the predominant symptom, behavioural and psychological treatment, dietary alterations, education, reassurance and effective patient-physician relationship. When evaluating for the stress-induced condition in the upper GI tract, the diagnostic testing includes mainly blood tests and gastroscopy to rule out GERD and peptic ulcer disease. The therapy for these conditions is mainly based on the inhibition of gastric acid by proton pump inhibitors and eradication of Helicobacter pylori-infection. Additionally, melatonin an important mediator of brain gut axis has been shown to exhibit important protective effects against stress-induced lesions in the gastrointestinal tract. Finally, probiotics may profoundly affect the brain-gut interactions ("microbiome-gut-brain axis") and attenuate the development of stress-induced disorders in both the upper and lower gastrointestinal tract. Further studies on the brain-gut axis are needed to open new therapeutic avenues in the future.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>Peter C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Thuringia Clinic Saalfeld, Teaching Hospital of the University Jena, Germany. pkonturek@thueringen-kliniken.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brzozowski</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Konturek</LastName><ForeName>S J</ForeName><Initials>SJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Poland</Country><MedlineTA>J Physiol Pharmacol</MedlineTA><NlmUniqueID>9114501</NlmUniqueID><ISSNLinking>0867-5910</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000930">Antidiarrheals</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000930" MajorTopicYN="N">Antidiarrheals</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017615" MajorTopicYN="N">Enteric Nervous System</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="N">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22314561</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37541528</PMID><DateCompleted><Year>2024</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1528-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>165</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Gastroenterology</Title><ISOAbbreviation>Gastroenterology</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.</ArticleTitle><Pagination><StartPage>1206</StartPage><EndPage>1218</EndPage><MedlinePgn>1206-1218</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1053/j.gastro.2023.07.018</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0016-5085(23)04838-2</ELocationID><Abstract><AbstractText Label="BACKGROUND &amp; AIMS">Some probiotics may be beneficial in irritable bowel syndrome (IBS), but differences in species and strains used, as well as endpoints reported, have hampered attempts to make specific recommendations as to which should be preferred. We updated our previous meta-analysis examining this issue.</AbstractText><AbstractText Label="METHODS">MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched (up to March 2023). Randomized controlled trials (RCTs) recruiting adults with IBS, comparing probiotics with placebo were eligible. Dichotomous symptom data were pooled to obtain a relative risk of global symptoms, abdominal pain, or abdominal bloating or distension persisting after therapy, with a 95% confidence interval (CI). Continuous data were pooled using a standardized mean difference with a 95% CI. Adverse events data were also pooled.</AbstractText><AbstractText Label="RESULTS">We identified 82 eligible trials, containing 10,332 patients. Only 24 RCTs were at low risk of bias across all domains. For global symptoms, there was moderate certainty in the evidence for a benefit of Escherichia strains, low certainty for Lactobacillus strains and Lactobacillus plantarum 299V, and very low certainty for combination probiotics, LacClean Gold S, Duolac 7s, and Bacillus strains. For abdominal pain, there was low certainty in the evidence for a benefit of Saccharomyces cerevisae I-3856 and Bifidobacterium strains, and very low certainty for combination probiotics, Lactobacillus, Saccharomyces, and Bacillus strains. For abdominal bloating or distension there was very low certainty in the evidence for a benefit of combination probiotics and Bacillus strains. The relative risk of experiencing any adverse event, in 55 trials, including more than 7000 patients, was not significantly higher with probiotics.</AbstractText><AbstractText Label="CONCLUSIONS">Some combinations of probiotics or strains may be beneficial in IBS. However, certainty in the evidence for efficacy by GRADE criteria was low to very low across almost all of our analyses.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khasawneh</LastName><ForeName>Mais</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Black</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quigley</LastName><ForeName>Eamonn M M</ForeName><Initials>EMM</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Lynda K. and David M. Underwood Center for Digestive Disorders, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moayyedi</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Gastroenterology Division, McMaster University, Health Sciences Center, Hamilton, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, United Kingdom; Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, United Kingdom. Electronic address: alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Gastroenterology</MedlineTA><NlmUniqueID>0374630</NlmUniqueID><ISSNLinking>0016-5085</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Gastroenterology. 2024 Mar;166(3):545-546. doi: 10.1053/j.gastro.2023.11.019.</RefSource><PMID Version="1">37979710</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Gastroenterology. 2024 Nov;167(6):1248. doi: 10.1053/j.gastro.2024.08.017.</RefSource><PMID Version="1">39207347</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="N">Gastrointestinal Microbiome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal Bloating</Keyword><Keyword MajorTopicYN="N">Abdominal Pain</Keyword><Keyword MajorTopicYN="N">Irritable Bowel Syndrome</Keyword><Keyword MajorTopicYN="N">Meta-analysis</Keyword><Keyword MajorTopicYN="N">Probiotics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>5</Month><Day>31</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>5</Day><Hour>5</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>4</Day><Hour>19</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37541528</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2023.07.018</ArticleId><ArticleId IdType="pii">S0016-5085(23)04838-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35433498</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>19</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2235-2988</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Frontiers in cellular and infection microbiology</Title><ISOAbbreviation>Front Cell Infect Microbiol</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Probiotics for Irritable Bowel Syndrome: A Systematic Review and Network Meta-Analysis.</ArticleTitle><Pagination><StartPage>859967</StartPage><MedlinePgn>859967</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">859967</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fcimb.2022.859967</ELocationID><Abstract><AbstractText Label="BACKGROUND">Irritable bowel syndrome (IBS) is a common gastrointestinal condition. Studies regarding the treatment of IBS with probiotics have not yielded consistent results, and the best probiotics has not yet been confirmed. Therefore, we performed a network meta-analysis (NMA) to assess the relative rank order of different probiotics for IBS.</AbstractText><AbstractText Label="METHOD">We searched for RCTs on the efficacy of probiotics for IBS until August 25, 2021. The primary outcome was the symptom relief rate, as well as global symptoms, abdominal pain, bloating, and straining scores. The NMA was conducted using Stata 15.0. We also used meta-regression to explore whether the treatment length and dose influenced the efficacy.</AbstractText><AbstractText Label="RESULTS">Forty-three RCTs, with 5,531 IBS patients, were included in this analysis. Firstly, we compared the efficacy of different probiotic species. <i>B.coagulans</i> exhibited the highest probability to be the optimal probiotic specie in improving IBS symptom relief rate, as well as global symptom, abdominal pain, bloating, and straining scores. In regard to the secondary outcomes, <i>L.plantarum</i> ranked first in ameliorating the QOL of IBS patients, but without any significant differences compared with other probiotic species in standardized mean differences (SMD) estimates. Moreover, patients received <i>L.acidophilus</i> had lowest incidence of adverse events. The meta-regression revealed that no significant differences were found between participants using different doses of probiotics in all outcomes, while the treatment length, as a confounder, can significantly influence the efficacy of probiotics in ameliorating abdominal pain (Coef = -2.30; p = 0.035) and straining (Coef = -3.15; p = 0.020) in IBS patients. Thus, we performed the subgroup analysis on treatment length subsequently in these two outcomes, which showed that efficacy of <i>B.coagulans</i> using 8 weeks ranked first both in improving the abdominal pain and straining scores. Additionally, <i>B. coagulans</i> still had significant efficacy compared to different types of probiotic combinations in present study.</AbstractText><AbstractText Label="CONCLUSIONS">The findings of this NMA suggested that <i>B.coagulans</i> had prominent efficacy in treating IBS patients, and incorporating <i>B.coagulans</i> into a probiotic combination, or genetically engineering it to amplify its biological function may be a future research target to treat IBS patients. With few direct comparisons available between individual therapies today, this NMA may have utility in forming treatment guideline for IBS with probiotics.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Zhang, Zhang, Zhang, Sun and Duan.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Tao</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cunzheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jindong</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Feng</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>China Center for Evidence Based Medical and Clinical Research, Peking University, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Public Health, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duan</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Peking University Third Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D000099094">Network Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Cell Infect Microbiol</MedlineTA><NlmUniqueID>101585359</NlmUniqueID><ISSNLinking>2235-2988</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015746" MajorTopicYN="N">Abdominal Pain</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adverse events</Keyword><Keyword MajorTopicYN="N">efficacy</Keyword><Keyword MajorTopicYN="N">irritable bowel syndrome</Keyword><Keyword MajorTopicYN="N">network meta-analysis</Keyword><Keyword MajorTopicYN="N">probiotics</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>18</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35433498</ArticleId><ArticleId IdType="pmc">PMC9010660</ArticleId><ArticleId IdType="doi">10.3389/fcimb.2022.859967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Abbas Z., Yakoob J., Jafri W., Ahmad Z., Azam Z., Usman M. W., et al. . (2014). Cytokine and Clinical Response to Saccharomyces Boulardii Therapy in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized Trial. Eur. J. Gastroenterol. Hepatol. 26, 630&#x2013;639. doi:&#xa0;10.1097/MEG.0000000000000094</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000094</ArticleId><ArticleId IdType="pubmed">24722560</ArticleId></ArticleIdList></Reference><Reference><Citation>Agrawal A., Houghton L. A., Morris J., Reilly B., Guyonnet D., Feuillerat. N., et al. . (2009). Clinical Trial: The Effects of a Fermented Milk Product Containing Bifidobacterium Lactis DN-173 010 on Abdominal Distension and Gastrointestinal Transit in Irritable Bowel Syndrome With Constipation. Aliment. Pharmacol. Ther. 29, 104&#x2013;114. doi:&#xa0;10.1111/j.1365-2036.2008.03853.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03853.x</ArticleId><ArticleId IdType="pubmed">18801055</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V., Gschossmann J., Layer P. (2020). Heat-Inactivated Bifidobacterium Bifidum MIMBb75 (SYN-HI-001) in the Treatment of Irritable Bowel Syndrome: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Clinical Trial. Lancet Gastroenterol. Hepatol. 5, 658&#x2013;666. doi:&#xa0;10.1016/S2468-1253(20)30056-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId><ArticleId IdType="pubmed">32277872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauserman M., Michail S. (2005). The Use of Lactobacillus GG in Irritable Bowel Syndrome in Children: A Double-Blind Randomized Control Trial. J. Pediatr. 147, 197&#x2013;201. doi:&#xa0;10.1016/j.jpeds.2005.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2005.05.015</ArticleId><ArticleId IdType="pubmed">16126049</ArticleId></ArticleIdList></Reference><Reference><Citation>Begtrup L. M., de Muckadell O. B., Kjeldsen J., Christensen R. D., Jarb&#xf8;l D. E.. (2013). Long-Term Treatment With Probiotics in Primary Care Patients With Irritable Bowel Syndrome&#x2013;a Randomised, Double-Blind, Placebo Controlled Trial. Scand. J. Gastroenterol. 48, 1127&#x2013;1135. doi:&#xa0;10.3109/00365521.2013.825314</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2013.825314</ArticleId><ArticleId IdType="pubmed">23957590</ArticleId></ArticleIdList></Reference><Reference><Citation>Black C. J., Ford A. C. (2020). Global Burden of Irritable Bowel Syndrome: Trends, Predictions and Risk Factors. Nat. Rev. Gastroenterol. Hepatol. 17, 473&#x2013;486. doi:&#xa0;10.1038/s41575-020-0286-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41575-020-0286-8</ArticleId><ArticleId IdType="pubmed">32296140</ArticleId></ArticleIdList></Reference><Reference><Citation>Camilleri M. (2021). Diagnosis and Treatment of Irritable Bowel Syndrome: A Review. JAMA 325, 865&#x2013;877. doi:&#xa0;10.1001/jama.2020.22532</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.22532</ArticleId><ArticleId IdType="pubmed">33651094</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabotti M., Scirocco A., Maselli M. A., Severi C.. (2015). The Gut-Brain Axis: Interactions Between Enteric Microbiota, Central and Enteric Nervous Systems. Ann. Gastroenterol. 28, 203&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4367209</ArticleId><ArticleId IdType="pubmed">25830558</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi C. H., Jo S. Y., Park H. J., Chang S. K., Byeon J. S., Myung S. J.. (2011). A Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Saccharomyces Boulardii in Irritable Bowel Syndrome: Effect on Quality of Life. J. Clin. Gastroenterol. 45, 679&#x2013;683. doi:&#xa0;10.1097/MCG.0b013e318204593e</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0b013e318204593e</ArticleId><ArticleId IdType="pubmed">21301358</ArticleId></ArticleIdList></Reference><Reference><Citation>Creed F., Ratcliffe J., Fernandez L., Tomenson B., Palmer S., Rigby C., et al. . (2001). Health-Related Quality of Life and Health Care Costs in Severe, Refractory Irritable Bowel Syndrome. Ann. Intern. Med. 134, 860&#x2013;868. doi:&#xa0;10.7326/0003-4819-134-9_part_2-200105011-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-134-9_part_2-200105011-00010</ArticleId><ArticleId IdType="pubmed">11346322</ArticleId></ArticleIdList></Reference><Reference><Citation>Dapoigny M., Piche T., Ducrotte P., Lunaud B., Cardot J. M., Bernalier-Donadille A.. (2012). Efficacy and Safety Profile of LCR35 Complete Freeze-Dried Culture in Irritable Bowel Syndrome: A Randomized, Double-Blind Study. World J. Gastroenterol. 18, 2067&#x2013;2075. doi:&#xa0;10.3748/wjg.v18.i17.2067</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i17.2067</ArticleId><ArticleId IdType="pmc">PMC3342605</ArticleId><ArticleId IdType="pubmed">22563194</ArticleId></ArticleIdList></Reference><Reference><Citation>Drouault-Holowacz S., Bieuvelet S., Burckel A., Cazaubiel M., Dray X., Marteau P.. (2008). A Double Blind Randomized Controlled Trial of a Probiotic Combination in 100 Patients With Irritable Bowel Syndrome. Gastroenterol. Clin. Biol. 32, 147&#x2013;152. doi:&#xa0;10.1016/j.gcb.2007.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gcb.2007.06.001</ArticleId><ArticleId IdType="pubmed">18387426</ArticleId></ArticleIdList></Reference><Reference><Citation>Ducrott&#xe9; P., Sawant P., Jayanthi V. (2012). Clinical Trial: Lactobacillus Plantarum 299v (DSM 9843) Improves Symptoms of Irritable Bowel Syndrome. World J. Gastroenterol. 18, 4012&#x2013;4018. doi:&#xa0;10.3748/wjg.v18.i30.4012</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v18.i30.4012</ArticleId><ArticleId IdType="pmc">PMC3419998</ArticleId><ArticleId IdType="pubmed">22912552</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Serag H. B., Olden K. (2002). Health-Related Quality of Life Among Persons With Irritable Bowel Syndrome: A Systematic Review. Aliment. Pharmacol. Ther. 16, 1171&#x2013;1185. doi:&#xa0;10.1046/j.1365-2036.2002.01290.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2002.01290.x</ArticleId><ArticleId IdType="pubmed">12030961</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshaghabee F., Rokana N., Gulhane R. D., Sharma C., Panwar H.. (2017). Bacillus As Potential Probiotics: Status, Concerns, and Future Perspectives. Front. Microbiol. 8. doi:&#xa0;10.3389/fmicb.2017.01490</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2017.01490</ArticleId><ArticleId IdType="pmc">PMC5554123</ArticleId><ArticleId IdType="pubmed">28848511</ArticleId></ArticleIdList></Reference><Reference><Citation>Enck P., Zimmermann K., Menke G., Klosterhalfen S.. (2009). Randomized Controlled Treatment Trial of Irritable Bowel Syndrome With a Probiotic E.-Coli Preparation (DSM17252) Compared to Placebo. Z Gastroenterol. 47, 209&#x2013;214. doi:&#xa0;10.1055/s-2008-1027702</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2008-1027702</ArticleId><ArticleId IdType="pubmed">19197823</ArticleId></ArticleIdList></Reference><Reference><Citation>Fond G., Loundou A., Hamdani N., Boukouaci W., Dargel A., Oliveira J., et al. . (2014). Anxiety and Depression Comorbidities in Irritable Bowel Syndrome (IBS): A Systematic Review and Meta-Analysis. Eur. Arch. Psychiatry Clin. Neurosci. 264, 651&#x2013;660. doi:&#xa0;10.1007/s00406-014-0502-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00406-014-0502-z</ArticleId><ArticleId IdType="pubmed">24705634</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford A. C., Harris L. A., Lacy B. E., Quigley E. M. M., Moayyedi P.. (2018). Systematic Review With Meta-Analysis: The Efficacy of Prebiotics, Probiotics, Synbiotics and Antibiotics in Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 48, 1044&#x2013;1060. doi:&#xa0;10.1111/apt.15001</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.15001</ArticleId><ArticleId IdType="pubmed">30294792</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudo S., Okumura T., Inamori M., Okuyama Y., Kanazawa M., Kamiya T., et al. . (2021). Evidence-Based Clinical Practice Guidelines for Irritable Bowel Syndrome 2020. J. Gastroenterol. 56 (3), 193&#x2013;217. doi: 10.1007/s00535-020-01746-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00535-020-01746-z</ArticleId><ArticleId IdType="pmc">PMC7932982</ArticleId><ArticleId IdType="pubmed">33538894</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayathri R., Aruna T., Malar S., Shilpa B., Dhanasekar K. R.. (2020). Efficacy of Saccharomyces Cerevisiae CNCM I-3856 as an Add-on Therapy for Irritable Bowel Syndrome. Int. J. Colorectal Dis. 35, 139&#x2013;145. doi:&#xa0;10.1007/s00384-019-03462-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-019-03462-4</ArticleId><ArticleId IdType="pubmed">31807856</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglielmetti S., Mora D., Gschwender M., Popp K.. (2011). Randomised Clinical Trial: Bifidobacterium Bifidum MIMBb75 Significantly Alleviates Irritable Bowel Syndrome and Improves Quality of Life&#x2013;A Double-Blind, Placebo-Controlled Study. Aliment. Pharmacol. Ther. 33, 1123&#x2013;1132. doi:&#xa0;10.1111/j.1365-2036.2011.04633.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2011.04633.x</ArticleId><ArticleId IdType="pubmed">21418261</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A. K., Maity C. (2021). Efficacy and Safety of Bacillus Coagulans LBSC in Irritable Bowel Syndrome: A Prospective, Interventional, Randomized, Double-Blind, Placebo-Controlled Clinical Study [CONSORT Compliant]. Med. (Baltimore) 100, e23641. doi:&#xa0;10.1097/MD.0000000000023641</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000023641</ArticleId><ArticleId IdType="pmc">PMC7837859</ArticleId><ArticleId IdType="pubmed">33545934</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyonnet D., Chassany O., Ducrotte P., Picard C., Mouret M., Mercier C. H., et al. . (2007). Effect of a Fermented Milk Containing Bifidobacterium Animalis DN-173 010 on the Health-Related Quality of Life and Symptoms in Irritable Bowel Syndrome in Adults in Primary Care: A Multicentre, Randomized, Double-Blind, Controlled Trial. Aliment. Pharmacol. Ther. 26, 475&#x2013;486. doi:&#xa0;10.1111/j.1365-2036.2007.03362.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03362.x</ArticleId><ArticleId IdType="pubmed">17635382</ArticleId></ArticleIdList></Reference><Reference><Citation>Gwee K. A., Gonlachanvit S., Ghoshal U. C., Chua A. S. B., Miwa H., Wu J., et al. . (2019). Second Asian Consensus on Irritable Bowel Syndrome. J. Neurogastroenterol. Motil. 25, 343&#x2013;362. doi:&#xa0;10.5056/jnm19041</Citation><ArticleIdList><ArticleId IdType="doi">10.5056/jnm19041</ArticleId><ArticleId IdType="pmc">PMC6657923</ArticleId><ArticleId IdType="pubmed">31327218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jafari E., Vahedi H., Merat S., Momtahen S., Riahi A.. (2014). Therapeutic Effects, Tolerability and Safety of a Multi-Strain Probiotic in Iranian Adults With Irritable Bowel Syndrome and Bloating. Arch. Iran Med. 17, 466&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">24979556</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir M. A., Ishaque S. M., Ali M. S., Mahmuduzzaman M., Hasan M.. (2011). Role of Saccharomyces Boulardii in Diarrhea Predominant Irritable Bowel Syndrome. Mymensingh Med. J. 20, 397&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pubmed">21804501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2005). A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: A Controlled 6-Month Intervention. Aliment. Pharmacol. Ther. 22, 387&#x2013;394. doi:&#xa0;10.1111/j.1365-2036.2005.02579.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2005.02579.x</ArticleId><ArticleId IdType="pubmed">16128676</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajander K., Myllyluoma E., Rajili&#x107;-Stojanovi&#x107; M., Kyr&#xf6;npalo S., Rasmussen M., J&#xe4;rvenp&#xe4;&#xe4; S., et al. . (2008). Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota. Aliment. Pharmacol. Ther. 27, 48&#x2013;57. doi:&#xa0;10.1111/j.1365-2036.2007.03542.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2007.03542.x</ArticleId><ArticleId IdType="pubmed">17919270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Camilleri M., McKinzie S., Lempke M. B., Burton D. D., Thomforde G. M., et al. . (2003). A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment Pharmacol. Ther. 17, 895&#x2013;904. doi:&#xa0;10.1046/j.1365-2036.2003.01543.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2036.2003.01543.x</ArticleId><ArticleId IdType="pubmed">12656692</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. J., Roque M. I. V., Camilleri M., Stephens D., Burton D. D., Baxter K., et al. . (2005). A Randomized Controlled Trial of a Probiotic Combination VSL# 3 and Placebo in Irritable Bowel Syndrome With Bloating. Neurogastroenterol. Motil. 17, 687&#x2013;696. doi:&#xa0;10.1111/j.1365-2982.2005.00695.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2982.2005.00695.x</ArticleId><ArticleId IdType="pubmed">16185307</ArticleId></ArticleIdList></Reference><Reference><Citation>King T. S., Elia M., Hunter J. O. (1998). Abnormal Colonic Fermentation in Irritable Bowel Syndrome. Lancet 352, 1187&#x2013;1189. doi:&#xa0;10.1016/s0140-6736(98)02146-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0140-6736(98)02146-1</ArticleId><ArticleId IdType="pubmed">9777836</ArticleId></ArticleIdList></Reference><Reference><Citation>Kligler B., Cohrssen A. (2008). Probiotics. Am. Fam Physician. 78, 1073&#x2013;1078. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pubmed">19007054</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruis W., et al. . (2012). A Double-Blind Placebo-Controlled Trial to Study Therapeutic Effects of Probiotic Escherichia Coli Nissle 1917 in Subgroups of Patients With Irritable Bowel Syndrome. Int. J. Colorectal Dis. 27, 467&#x2013;474. doi:&#xa0;10.1007/s00384-011-1363-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00384-011-1363-9</ArticleId><ArticleId IdType="pmc">PMC3307993</ArticleId><ArticleId IdType="pubmed">22130826</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Pimentel M., Brenner D. M., Chey W. D., Keefer L. A., Long M. D., et al. . (2021). ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am. J. Gastroenterol. 116, 17&#x2013;44. doi:&#xa0;10.14309/ajg.0000000000001036</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId><ArticleId IdType="pubmed">33315591</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy B. E., Patel N. K. (2017). Rome Criteria and a Diagnostic Approach to Irritable Bowel Syndrome. J. Clin. Med. 6, 99. doi:&#xa0;10.3390/jcm6110099</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm6110099</ArticleId><ArticleId IdType="pmc">PMC5704116</ArticleId><ArticleId IdType="pubmed">29072609</ArticleId></ArticleIdList></Reference><Reference><Citation>Ligaarden S. C., Axelsson L., Naterstad K., Lydersen S., Farup P. G.. (2010). A Candidate Probiotic With Unfavourable Effects in Subjects With Irritable Bowel Syndrome: A Randomised Controlled Trial. BMC Gastroenterol. 10, 16. doi:&#xa0;10.1186/1471-230X-10-16</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-10-16</ArticleId><ArticleId IdType="pmc">PMC2831047</ArticleId><ArticleId IdType="pubmed">20144246</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Zhang L., Wang X., Wang Z., Zhang J., Jiang R., et al. . (2016). Similar Fecal Microbiota Signatures in Patients With Diarrhea-Predominant Irritable Bowel Syndrome and Patients With Depression. Clin. Gastroenterol. Hepatol. 14, 1602&#x2013;1611.e5. doi:&#xa0;10.1016/j.cgh.2016.05.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2016.05.033</ArticleId><ArticleId IdType="pubmed">27266978</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra A., Hillil&#xe4; M., Huttunen T., M&#xe4;nnikk&#xf6; S., Taalikka M., Tennil&#xe4; J., et al. . (2016). Irritable Bowel Syndrome Symptom Severity Improves Equally With Probiotic and Placebo. World J. Gastroenterol. 22, 10631&#x2013;10642. doi:&#xa0;10.3748/wjg.v22.i48.10631</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v22.i48.10631</ArticleId><ArticleId IdType="pmc">PMC5192275</ArticleId><ArticleId IdType="pubmed">28082816</ArticleId></ArticleIdList></Reference><Reference><Citation>Madempudi R. S., Ahire J. J., Neelamraju J., Tripathi A., Nanal S.. (2019). Randomized Clinical Trial: The Effect of Probiotic Bacillus Coagulans Unique IS2 vs. Placebo on the Symptoms Management of Irritable Bowel Syndrome in Adults. Sci. Rep. 9, 12210. doi:&#xa0;10.1038/s41598-019-48554-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-48554-x</ArticleId><ArticleId IdType="pmc">PMC6704184</ArticleId><ArticleId IdType="pubmed">31434935</ArticleId></ArticleIdList></Reference><Reference><Citation>Maity C., Gupta A. K., Saroj D. B., Biyani A., Bagkar P., Kulkarni J., et al. . (2020). Impact of a Gastrointestinal Stable Probiotic Supplement Bacillus Coagulans LBSC on Human Gut Microbiome Modulation. J. Diet Suppl.18, 577&#x2013;596. doi:&#xa0;10.1080/19390211.2020.1814931</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19390211.2020.1814931</ArticleId><ArticleId IdType="pubmed">32896190</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed M., Nagabhushanam K., Natarajan S., Sivakumar A., Ali F., Pande A., et al. . (2016). Bacillus Coagulans MTCC 5856 Supplementation in the Management of Diarrhea Predominant Irritable Bowel Syndrome: A Double Blind Randomized Placebo Controlled Pilot Clinical Study. Nutr. J. 15, 21. doi:&#xa0;10.1186/s12937-016-0140-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12937-016-0140-6</ArticleId><ArticleId IdType="pmc">PMC4769834</ArticleId><ArticleId IdType="pubmed">26922379</ArticleId></ArticleIdList></Reference><Reference><Citation>Martoni C. J., Srivastava S., Leyer G. J. (2020). Lactobacillus Acidophilus DDS-1 and Bifidobacterium Lactis UABla-12 Improve Abdominal Pain Severity and Symptomology in Irritable Bowel Syndrome: Randomized Controlled Trial. Nutrients 12, 363. doi:&#xa0;10.3390/nu12020363</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu12020363</ArticleId><ArticleId IdType="pmc">PMC7071206</ArticleId><ArticleId IdType="pubmed">32019158</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F., Lacy B. E., Chang L., Chey W. D., Lembo A. J., Simren M., et al. . (2016). Bowel Disorders. Gastroenterology S0016&#x2013;5085(16)00222-5. doi:&#xa0;10.1053/j.gastro.2016.02.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId><ArticleId IdType="pubmed">27144627</ArticleId></ArticleIdList></Reference><Reference><Citation>Moayyedi P., Andrews C. N., MacQueen G., Korownyk C., Marsiglio M., Graff L., et al. . (2019). Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Irritable Bowel Syndrome (IBS). J. Can. Assoc. Gastroenterol. 2, 6&#x2013;29. doi:&#xa0;10.1093/jcag/gwy071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jcag/gwy071</ArticleId><ArticleId IdType="pmc">PMC6507291</ArticleId><ArticleId IdType="pubmed">31294724</ArticleId></ArticleIdList></Reference><Reference><Citation>Mu Y., Cong Y. (2019). Bacillus Coagulans and its Applications in Medicine. Benef. Microbes 10, 679&#x2013;688. doi:&#xa0;10.3920/BM2019.0016</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2019.0016</ArticleId><ArticleId IdType="pubmed">31203635</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng Q. X., et al. . (2018). A Meta-Analysis of the Use of Probiotics to Alleviate Depressive Symptoms. J. Affect. Disord. 228, 13&#x2013;19. doi:&#xa0;10.1016/j.jad.2017.11.063</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2017.11.063</ArticleId><ArticleId IdType="pubmed">29197739</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedzielin K., Kordecki H., Birkenfeld B. (2001). A Controlled, Double-Blind, Randomized Study on the Efficacy of Lactobacillus Plantarum 299V in Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 13, 1143&#x2013;1147. doi:&#xa0;10.1097/00042737-200110000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00042737-200110000-00004</ArticleId><ArticleId IdType="pubmed">11711768</ArticleId></ArticleIdList></Reference><Reference><Citation>Niv E., Naftali T., Hallak R., Vaisman N.. (2005). The Efficacy of Lactobacillus Reuteri ATCC 55730 in the Treatment of Patients With Irritable Bowel Syndrome&#x2013;A Double Blind, Placebo-Controlled, Randomized Study. Clin. Nutr. 24, 925&#x2013;931. doi:&#xa0;10.1016/j.clnu.2005.06.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clnu.2005.06.001</ArticleId><ArticleId IdType="pubmed">16051399</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P., Parr H., Barberio B., Black C. J., Savarino E. V., Ford A. C.. (2020). Global Prevalence of Irritable Bowel Syndrome According to Rome III or IV Criteria: A Systematic Review and Meta-Analysis. Lancet Gastroenterol. Hepatol. 5, 908&#x2013;917. doi:&#xa0;10.1016/S2468-1253(20)30217-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId><ArticleId IdType="pubmed">32702295</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L., McCarthy J., Kelly P., Hurley G., Luo F., Chen K., et al. . (2005). Lactobacillus and Bifidobacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles. Gastroenterology 128, 541&#x2013;551. doi:&#xa0;10.1053/j.gastro.2004.11.050</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId><ArticleId IdType="pubmed">15765388</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Sullivan M. A., O&#x2019;Morain C. A. (2000). Bacterial Supplementation in the Irritable Bowel Syndrome. A Randomised Double-Blind Placebo-Controlled Crossover Study. Dig. Liver Dis. 32, 294&#x2013;301. doi:&#xa0;10.1016/s1590-8658(00)80021-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1590-8658(00)80021-3</ArticleId><ArticleId IdType="pubmed">11515626</ArticleId></ArticleIdList></Reference><Reference><Citation>Page M. J., McKenzie J. E., Bossuyt P. M., Boutron I., Hoffmann T. C., Mulrow C. D., et al. . (2021). The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. PloS Med. 18, e1003583. doi:&#xa0;10.1371/journal.pmed.1003583</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003583</ArticleId><ArticleId IdType="pmc">PMC8007028</ArticleId><ArticleId IdType="pubmed">33780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineton D. C. G., Neut C., Chau A., Cazaubiel M., Pelerin F., Justen P., et al. . (2015). A Randomized Clinical Trial of Saccharomyces Cerevisiae Versus Placebo in the Irritable Bowel Syndrome. Dig. Liver Dis. 47, 119&#x2013;124. doi:&#xa0;10.1016/j.dld.2014.11.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2014.11.007</ArticleId><ArticleId IdType="pubmed">25488056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez M. I., Hall G. B., Ghajar K., Nardelli A., Bolino C., Lau J. T., et al. . (2017). Probiotic Bifidobacterium Longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology 153, 448&#x2013;459.e8. doi:&#xa0;10.1053/j.gastro.2017.05.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId><ArticleId IdType="pubmed">28483500</ArticleId></ArticleIdList></Reference><Reference><Citation>Plaza-Diaz J., Gomez-Llorente C., Fontana L., Gil A. (2014). Modulation of Immunity and Inflammatory Gene Expression in the Gut, in Inflammatory Diseases of the Gut and in the Liver by Probiotics. World J. Gastroenterol. 20, 15632&#x2013;15649. doi:&#xa0;10.3748/wjg.v20.i42.15632</Citation><ArticleIdList><ArticleId IdType="doi">10.3748/wjg.v20.i42.15632</ArticleId><ArticleId IdType="pmc">PMC4229528</ArticleId><ArticleId IdType="pubmed">25400447</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston K., Krumian R., Hattner J., de Montigny D., Stewart M., Gaddam S. (2018). Lactobacillus Acidophilus CL1285, Lactobacillus Casei LBC80R and Lactobacillus Rhamnosus CLR2 Improve Quality-of-Life and IBS Symptoms: A Double-Blind, Randomised, Placebo-Controlled Study. Benef. Microbes 9, 697&#x2013;706. doi:&#xa0;10.3920/BM2017.0105</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0105</ArticleId><ArticleId IdType="pubmed">29888656</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J., Li R., Raes J., Arumugam M., Burgdorf K. S., Manichanh C., et al. . (2010). A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing. Nature 464, 59&#x2013;65. doi:&#xa0;10.1038/nature08821</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08821</ArticleId><ArticleId IdType="pmc">PMC3779803</ArticleId><ArticleId IdType="pubmed">20203603</ArticleId></ArticleIdList></Reference><Reference><Citation>Raskov H., Burcharth J., Pommergaard H. C., Rosenberg J. (2016). Irritable Bowel Syndrome, the Microbiota and the Gut-Brain Axis. Gut Microbes 7, 365&#x2013;383. doi:&#xa0;10.1080/19490976.2016.1218585</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/19490976.2016.1218585</ArticleId><ArticleId IdType="pmc">PMC5046167</ArticleId><ArticleId IdType="pubmed">27472486</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T., Goldsmith J. R., Carroll I. M., Barros S. P., Palsson O., Jobin C., et al. . (2014). Lactobacillus Acidophilus NCFM Affects Colonic Mucosal Opioid Receptor Expression in Patients With Functional Abdominal Pain - a Randomised Clinical Study. Aliment. Pharmacol. Ther. 40, 200&#x2013;207. doi:&#xa0;10.1111/apt.12800</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apt.12800</ArticleId><ArticleId IdType="pmc">PMC4613798</ArticleId><ArticleId IdType="pubmed">24853043</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel Y., Ringel-Kulka T. (2015). The Intestinal Microbiota and Irritable Bowel Syndrome. J. Clin. Gastroenterol. 49 Suppl 1, S56&#x2013;S59. doi:&#xa0;10.1097/MCG.0000000000000418</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCG.0000000000000418</ArticleId><ArticleId IdType="pubmed">26447966</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts L. M., McCahon D., Holder R., Wilson S., Hobbs F. D. (2013). A Randomised Controlled Trial of a Probiotic &#x2018;Functional Food&#x2019; in the Management of Irritable Bowel Syndrome. BMC Gastroenterol. 13, 45. doi:&#xa0;10.1186/1471-230X-13-45</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-230X-13-45</ArticleId><ArticleId IdType="pmc">PMC3605320</ArticleId><ArticleId IdType="pubmed">23496803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C., Thuru X., Gelot A., Barnich N., Neut C., Dubuquoy L., et al. . (2007). Lactobacillus Acidophilus Modulates Intestinal Pain and Induces Opioid and Cannabinoid Receptors. Nat. Med. 13, 35&#x2013;37. doi:&#xa0;10.1038/nm1521</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1521</ArticleId><ArticleId IdType="pubmed">17159985</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf8;ndergaard B., Olsson J., Ohlson K., Svensson U., Bytzer P., Ekesbo R. (2011). Effects of Probiotic Fermented Milk on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome: A Randomized, Placebo-Controlled Trial. Scand. J. Gastroenterol. 46, 663&#x2013;672. doi:&#xa0;10.3109/00365521.2011.565066</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365521.2011.565066</ArticleId><ArticleId IdType="pubmed">21443416</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadrin S., Sennoune S., Gout B., Marque S., Moreau J., Zinoune K., et al. . (2020). A 2-Strain Mixture of Lactobacillus Acidophilus in the Treatment of Irritable Bowel Syndrome: A Placebo-Controlled Randomized Clinical Trial. Dig. Liver Dis. 52, 534&#x2013;540. doi:&#xa0;10.1016/j.dld.2019.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dld.2019.12.009</ArticleId><ArticleId IdType="pubmed">31952938</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt C. (2015). Mental Health: Thinking From the Gut. Nature 518, S12&#x2013;S15. doi:&#xa0;10.1038/518S13a</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/518S13a</ArticleId><ArticleId IdType="pubmed">25715275</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinn D. H., Song J. H., Kim H. J., Lee J. H., Son H. J., Chang D. K., et al. . (2008). Therapeutic Effect of Lactobacillus Acidophilus-SDC 2012, 2013 in Patients With Irritable Bowel Syndrome. Dig. Dis. Sci. 53, 2714&#x2013;2718. doi:&#xa0;10.1007/s10620-007-0196-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-007-0196-4</ArticleId><ArticleId IdType="pubmed">18274900</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiegel B. M., Gralnek I. M., Bolus R., Chang L., Dulai G. S., Mayer E. A., et al. . (2004). Clinical Determinants of Health-Related Quality of Life in Patients With Irritable Bowel Syndrome. Arch. Intern. Med. 164, 1773&#x2013;1780. doi:&#xa0;10.1001/archinte.164.16.1773</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.164.16.1773</ArticleId><ArticleId IdType="pubmed">15364671</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiller R., Pelerin F., Cayzeele D. A., Maudet C., Housez B., Cazaubiel M., et al. . (2016). Randomized Double Blind Placebo-Controlled Trial of Saccharomyces Cerevisiae CNCM I-3856 in Irritable Bowel Syndrome: Improvement in Abdominal Pain and Bloating in Those With Predominant Constipation. U. Eur. Gastroenterol. J. 4, 353&#x2013;362. doi:&#xa0;10.1177/2050640615602571</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2050640615602571</ArticleId><ArticleId IdType="pmc">PMC4924426</ArticleId><ArticleId IdType="pubmed">27403301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevenson C., Blaauw R., Fredericks E., Visser J., Roux S.. (2014). Randomized Clinical Trial: Effect of Lactobacillus Plantarum 299 V on Symptoms of Irritable Bowel Syndrome. Nutrition 30, 1151&#x2013;1157. doi:&#xa0;10.1016/j.nut.2014.02.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nut.2014.02.010</ArticleId><ArticleId IdType="pubmed">25194614</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudha M. R., Jayanthi N., Aasin M., Dhanashri R. D., Anirudh T. (2018). Efficacy of Bacillus Coagulans Unique IS2 in Treatment of Irritable Bowel Syndrome in Children: A Double Blind, Randomised Placebo Controlled Study. Benef. Microbes 9, 563&#x2013;572. doi:&#xa0;10.3920/BM2017.0129</Citation><ArticleIdList><ArticleId IdType="doi">10.3920/BM2017.0129</ArticleId><ArticleId IdType="pubmed">29695183</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2018). The Effect of Clostridium Butyricum on Symptoms and Fecal Microbiota in Diarrhea-Dominant Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Sci. Rep. 8, 2964. doi:&#xa0;10.1038/s41598-018-21241-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-21241-z</ArticleId><ArticleId IdType="pmc">PMC5813237</ArticleId><ArticleId IdType="pubmed">29445178</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen A. Y., Li M., Li Y. Y., Li L. X., Zhai W. Z., Wang P. (2016). Efficacy of Lactobacillus Casei Shirota for Patients With Irritable Bowel Syndrome. Eur. J. Gastroenterol. Hepatol. 28, 8&#x2013;14. doi:&#xa0;10.1097/MEG.0000000000000484</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MEG.0000000000000484</ArticleId><ArticleId IdType="pubmed">26469356</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant D. H., Paine P. A., Black C. J., Houghton L. A., Everitt H. A., Corsetti M., et al. . (2021). British Society of Gastroenterology Guidelines on the Management of Irritable Bowel Syndrome. Gut 70, 1214&#x2013;1240. doi:&#xa0;10.1136/gutjnl-2021-324598</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId><ArticleId IdType="pubmed">33903147</ArticleId></ArticleIdList></Reference><Reference><Citation>Whorwell P. J., Altringer L., Morel J., Bond Y., Charbonneau D., O'Mahony L., et al. . (2006). Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Women With Irritable Bowel Syndrome. Am. J. Gastroenterol. 101, 1581&#x2013;1590. doi:&#xa0;10.1111/j.1572-0241.2006.00734.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00734.x</ArticleId><ArticleId IdType="pubmed">16863564</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkins T., Sequoia J. (2017). Probiotics for Gastrointestinal Conditions: A Summary of the Evidence. Am. Fam Physician. 96, 170&#x2013;178. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">28762696</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong R. K., Yang C., Song G. H., Wong J., Ho K. Y. (2015). Melatonin Regulation as a Possible Mechanism for Probiotic (VSL#3) in Irritable Bowel Syndrome: A Randomized Double-Blinded Placebo Study. Dig. Dis. Sci. 60, 186&#x2013;194. doi:&#xa0;10.1007/s10620-014-3299-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10620-014-3299-8</ArticleId><ArticleId IdType="pubmed">25092036</ArticleId></ArticleIdList></Reference><Reference><Citation>Yano J. M., Yu K., Donaldson G. P., Shastri G. G., Ann P., Ma L., et al. . (2015). Indigenous Bacteria From the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell 161, 264&#x2013;276. doi:&#xa0;10.1016/j.cell.2015.02.047</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.02.047</ArticleId><ArticleId IdType="pmc">PMC4393509</ArticleId><ArticleId IdType="pubmed">25860609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng J., Li Y. Q., Zuo X. L., Zhen Y. B., Yang J., Liu C. H. (2008). Clinical Trial: Effect of Active Lactic Acid Bacteria on Mucosal Barrier Function in Patients With Diarrhoea-Predominant Irritable Bowel Syndrome. Aliment. Pharmacol. Ther. 28, 994&#x2013;1002. doi:&#xa0;10.1111/j.1365-2036.2008.03818.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2036.2008.03818.x</ArticleId><ArticleId IdType="pubmed">18671775</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37184752</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>22</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1950</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Drugs</Title><ISOAbbreviation>Drugs</ISOAbbreviation></Journal><ArticleTitle>Antibiotics and Probiotics for Irritable Bowel Syndrome.</ArticleTitle><Pagination><StartPage>687</StartPage><EndPage>699</EndPage><MedlinePgn>687-699</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40265-023-01871-y</ELocationID><Abstract><AbstractText>Irritable bowel syndrome (IBS) is a disorder of a gut-brain interaction characterised by abdominal pain and a change in stool form or frequency. Current symptom-based definitions and the classification of IBS promote heterogeneity amongst patients, meaning that there may be several different pathophysiological abnormalities leading to similar symptoms. Although our understanding of IBS is incomplete, there are several indicators that the microbiome may be involved in a subset of patients. Techniques including a faecal sample analysis, colonic biopsies, duodenal aspirates or surrogate markers, such as breath testing, have been used to examine the gut microbiota in individuals with IBS. Because of a lack of a clear definition of what constitutes a healthy gut microbiota, and the fact that alterations in gut microbiota have only been shown to be associated with IBS, a causal relationship is yet to be established. We discuss several hypotheses as to how dysbiosis may be responsible for IBS symptoms, as well as potential treatment strategies. We review the current evidence for the use of antibiotics and probiotics to alter the microbiome in an attempt to improve IBS symptoms. Rifaximin, a non-absorbable antibiotic, is the most studied antibiotic and has now been licensed for use in IBS with diarrhoea in the USA, but the drug remains unavailable in many countries for this indication. Current evidence also suggests that certain probiotics, including Lactobacillus plantarum DSM 9843 and Bifidobacterium bifidum MIMBb75, may be efficacious in some patients with IBS. Finally, we describe the future challenges facing us in our attempt to modulate the microbiome to treat IBS.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodoory</LastName><ForeName>Vivek C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ford</LastName><ForeName>Alexander C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leeds Gastroenterology Institute, St. James's University Hospital, Room 125, 4th Floor, Bexley Wing, Beckett Street, Leeds, LS9 7TF, UK. alexf12399@yahoo.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drugs</MedlineTA><NlmUniqueID>7600076</NlmUniqueID><ISSNLinking>0012-6667</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L36O5T016N</RegistryNumber><NameOfSubstance UI="D000078262">Rifaximin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000078262" MajorTopicYN="N">Rifaximin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="Y">Probiotics</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003967" MajorTopicYN="N">Diarrhea</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>13</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>15</Day><Hour>11</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37184752</ArticleId><ArticleId IdType="doi">10.1007/s40265-023-01871-y</ArticleId><ArticleId IdType="pii">10.1007/s40265-023-01871-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99-114.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32294476</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.04.014</ArticleId></ArticleIdList></Reference><Reference><Citation>Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">32702295</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30217-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049223</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)31548-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">28404070</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(16)30023-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Drossman DA, Talley NJ, Ruddy J, Ford AC. Functional gastrointestinal disorders: advances in understanding and management. Lancet. 2020;396(10263):1664&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049221</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(20)32115-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Craig O, Gracie DJ, Ford AC. Comparison of the Rome IV criteria with the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care. Gut. 2021;70(6):1110&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32973070</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-322519</ArticleId></ArticleIdList></Reference><Reference><Citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2016.02.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am J Gastroenterol. 2008;103(5):1229&#x2013;39 (quiz 40).</Citation><ArticleIdList><ArticleId IdType="pubmed">18371141</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2007.01740.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Staller K, Olen O, Soderling J, Roelstraete B, Tornblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a nationwide prospective cohort study. Am J Gastroenterol. 2020;115(5):746&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">32108661</ArticleId><ArticleId IdType="pmc">7196022</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000573</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang JY, Locke GR 3rd, McNally MA, Halder SL, Schleck CD, Zinsmeister AR, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">20160713</ArticleId><ArticleId IdType="pmc">2887253</ArticleId><ArticleId IdType="doi">10.1038/ajg.2010.40</ArticleId></ArticleIdList></Reference><Reference><Citation>Pace F, Molteni P, Bollani S, Sarzi-Puttini P, Stockbrugger R, Bianchi Porro G, et al. Inflammatory bowel disease versus irritable bowel syndrome: a hospital-based, case-control study of disease impact on quality of life. Scand J Gastroenterol. 2003;38(10):1031&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">14621276</ArticleId><ArticleId IdType="doi">10.1080/00365520310004524</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Guthrie EA, Ng CE, Black CJ, Ford AC. Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57:323&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">36544055</ArticleId><ArticleId IdType="doi">10.1111/apt.17356</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Impact of Rome IV irritable bowel syndrome on work and activities of daily living. Aliment Pharmacol Ther. 2022;56(5):844&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">35794733</ArticleId><ArticleId IdType="pmc">9543519</ArticleId><ArticleId IdType="doi">10.1111/apt.17132</ArticleId></ArticleIdList></Reference><Reference><Citation>Buono JL, Carson RT, Flores NM. Health-related quality of life, work productivity, and indirect costs among patients with irritable bowel syndrome with diarrhea. Health Qual Life Outcomes. 2017;15(1):35.</Citation><ArticleIdList><ArticleId IdType="pubmed">28196491</ArticleId><ArticleId IdType="pmc">5310011</ArticleId><ArticleId IdType="doi">10.1186/s12955-017-0611-2</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Jakobsson S, Simren M. Work productivity and activity impairment in irritable bowel syndrome (IBS): a multifaceted problem. Am J Gastroenterol. 2018;113(10):1540&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30254230</ArticleId><ArticleId IdType="doi">10.1038/s41395-018-0262-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Frandemark A, Tornblom H, Simren M, Jakobsson S. Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with irritable bowel syndrome. BMC Gastroenterol. 2022;22(1):73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35183112</ArticleId><ArticleId IdType="pmc">8858507</ArticleId><ArticleId IdType="doi">10.1186/s12876-022-02158-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Corney RH, Stanton R. Physical symptom severity, psychological and social dysfunction in a series of outpatients with irritable bowel syndrome. J Psychosom Res. 1990;34(5):483&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">2231481</ArticleId><ArticleId IdType="doi">10.1016/0022-3999(90)90022-V</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballou S, McMahon C, Lee HN, Katon J, Shin A, Rangan V, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America Survey. Clin Gastroenterol Hepatol. 2019;17(12):2471-8.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">31419572</ArticleId><ArticleId IdType="pmc">7675784</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.08.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, CLINICAL, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020;18(2):392-8.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">31154027</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2019.05.037</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P, et al. Irritable bowel syndrome is significantly associated with somatisation in 840 patients, which may drive bloating. Aliment Pharmacol Ther. 2015;41(5):449&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">25586008</ArticleId><ArticleId IdType="doi">10.1111/apt.13074</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Mikocka-Walus A, Yiannakou Y, Houghton LA, Black CJ, Ford AC. Impact of psychological comorbidity on the prognosis of irritable bowel syndrome. Am J Gastroenterol. 2021;116(7):1485&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">33840729</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001247</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022;56(1):110&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">35491477</ArticleId><ArticleId IdType="pmc">9325446</ArticleId><ArticleId IdType="doi">10.1111/apt.16939</ArticleId></ArticleIdList></Reference><Reference><Citation>Flacco ME, Manzoli L, De Giorgio R, Gasbarrini A, Cicchetti A, Bravi F, et al. Costs of irritable bowel syndrome in European countries with universal healthcare coverage: a meta-analysis. Eur Rev Med Pharmacol Sci. 2019;23(7):2986&#x2013;3000.</Citation><ArticleIdList><ArticleId IdType="pubmed">31002149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Xiang W, Li CY, Li SC. Economic burden of irritable bowel syndrome in China. World J Gastroenterol. 2016;22(47):10450&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058026</ArticleId><ArticleId IdType="pmc">5175258</ArticleId><ArticleId IdType="doi">10.3748/wjg.v22.i47.10450</ArticleId></ArticleIdList></Reference><Reference><Citation>Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156(1):254-72.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">30315778</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.063</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Salwen-Deremer JK, Gibson PR, Muir JG, Eswaran S, Chey WD. Comparing costs and outcomes of treatments for irritable bowel syndrome with diarrhea: cost-benefit analysis. Clin Gastroenterol Hepatol. 2022;20(1):136-44.e31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33010413</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2020.09.043</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Chang L, Salwen-Deremer JK, Gibson PR, Keefer L, Muir JG, et al. Contrasting clinician and insurer perspectives to managing irritable bowel syndrome: multilevel modeling analysis. Am J Gastroenterol. 2021;116(4):748&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pubmed">33982945</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000989</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodoory VC, Ng CE, Black CJ, Ford AC. Willingness to pay for medications among patients with Rome IV irritable bowel syndrome. Neurogastroenterol Motil. 2023;35(2): e14483.</Citation><ArticleIdList><ArticleId IdType="pubmed">36178331</ArticleId><ArticleId IdType="doi">10.1111/nmo.14483</ArticleId></ArticleIdList></Reference><Reference><Citation>Halpert A. Irritable bowel syndrome: patient-provider interaction and patient education. J Clin Med. 2018;7(1):3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29301273</ArticleId><ArticleId IdType="pmc">5791011</ArticleId><ArticleId IdType="doi">10.3390/jcm7010003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hearn M, Whorwell PJ, Vasant DH. Stigma and irritable bowel syndrome: a taboo subject? Lancet Gastroenterol Hepatol. 2020;5(6):607&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">31924568</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30348-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasant DH, Paine PA, Black CJ, Houghton LA, Everitt HA, Corsetti M, et al. British Society of Gastroenterology guidelines on the management of irritable bowel syndrome. Gut. 2021;70(7):1214&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">33903147</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-324598</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021;116(1):17&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">33315591</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001036</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Camilleri M, Earnest DL, Quigley EM, Moayyedi P, et al. Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis. Gut. 2020;69(1):74&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30996042</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-318160</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Burr NE, Quigley EMM, Moayyedi P, Houghton LA, Ford AC. Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis. Gastroenterology. 2018;155(6):1753&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">30144426</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2018.08.021</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Staudacher HM, Ford AC. Efficacy of a low FODMAP diet in irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2022;71:1117&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">34376515</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325214</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Thakur ER, Houghton LA, Quigley EMM, Moayyedi P, Ford AC. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut. 2020;69(8):1441&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">32276950</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2020-321191</ArticleId></ArticleIdList></Reference><Reference><Citation>Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31859183</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(19)30324-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Barberio B, Savarino EV, Black CJ, Ford AC. Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. Clin Gastroenterol Hepatol. 2021. https://doi.org/10.1016/j.cgh.2021.08.025 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cgh.2021.08.025</ArticleId><ArticleId IdType="pubmed">34425274</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JK, Thabane M, Garg AX, Clark WF, Moayyedi P, Collins SM, et al. Eight year prognosis of postinfectious irritable bowel syndrome following waterborne bacterial dysentery. Gut. 2010;59(5):605&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">20427395</ArticleId><ArticleId IdType="doi">10.1136/gut.2009.202234</ArticleId></ArticleIdList></Reference><Reference><Citation>Klem F, Wadhwa A, Prokop LJ, Sundt WJ, Farrugia G, Camilleri M, et al. Prevalence, risk factors, and outcomes of irritable bowel syndrome after infectious enteritis: a systematic review and meta-analysis. Gastroenterology. 2017;152(5):1042-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28069350</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.12.039</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalanka-Tuovinen J, Salojarvi J, Salonen A, Immonen O, Garsed K, Kelly FM, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63(11):1737&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">24310267</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-305994</ArticleId></ArticleIdList></Reference><Reference><Citation>David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">24336217</ArticleId><ArticleId IdType="doi">10.1038/nature12820</ArticleId></ArticleIdList></Reference><Reference><Citation>Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ. 2012;111(1):17&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22533211</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">21208106</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1004409</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Pimentel M, Rao SS, Schoenfeld P, Cash B, Weinstock LB, et al. Repeat treatment with rifaximin is safe and effective in patients with diarrhea-predominant irritable bowel syndrome. Gastroenterology. 2016;151(6):1113&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">27528177</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.08.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Spiegel BM, Talley NJ, Moayyedi P. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(12):1279&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">19602448</ArticleId><ArticleId IdType="doi">10.1016/j.cgh.2009.06.031</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ED, Basseri RJ, Chong K, Pimentel M. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55(9):2441&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20467896</ArticleId><ArticleId IdType="doi">10.1007/s10620-010-1276-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Talley NJ, Jones M, Kendall BJ, Koloski N, Walker MM, et al. Small intestinal bacterial overgrowth in irritable bowel wyndrome: a systematic review and meta-analysis of case-control studies. Am J Gastroenterol. 2020;115(2):190&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31913194</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol. 2000;95(12):3503&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">11151884</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2000.03368.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianiro G, Eusebi LH, Black CJ, Gasbarrini A, Cammarota G, Ford AC. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50(3):240&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31136009</ArticleId><ArticleId IdType="doi">10.1111/apt.15330</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Winkel R, Casen C, Hausken T, Gilja OH, Hatlebakk JG. Efficacy of fecal microbiota transplantation for patients with irritable bowel syndrome at 3 years after transplantation. Gastroenterology. 2022;163(4):982-94.e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">35709830</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.020</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Toole PW, Flemer B. From culture to high-throughput sequencing and beyond: a layperson&#x2019;s guide to the &#x201c;omics&#x201d; and diagnostic potential of the microbiome. Gastroenterol Clin North Am. 2017;46(1):9&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28164855</ArticleId><ArticleId IdType="doi">10.1016/j.gtc.2016.09.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugerth LW, Andreasson A, Talley NJ, Forsberg AM, Kjellstrom L, Schmidt PT, et al. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 2020;69(6):1076&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">31601615</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-318717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tap J, Derrien M, Tornblom H, Brazeilles R, Cools-Portier S, Dore J, et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology. 2017;152(1):111-23.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27725146</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.09.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg G, Rybakova D, Fischer D, Cernava T, Verges MC, Charles T, et al. Microbiome definition re-visited: old concepts and new challenges. Microbiome. 2020;8(1):103.</Citation><ArticleIdList><ArticleId IdType="pubmed">32605663</ArticleId><ArticleId IdType="pmc">7329523</ArticleId><ArticleId IdType="doi">10.1186/s40168-020-00875-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464(7285):59&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">20203603</ArticleId><ArticleId IdType="pmc">3779803</ArticleId><ArticleId IdType="doi">10.1038/nature08821</ArticleId></ArticleIdList></Reference><Reference><Citation>Sender R, Fuchs S, Milo R. Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans. Cell. 2016;164(3):337&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">26824647</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2016.01.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018;361: k2179.</Citation><ArticleIdList><ArticleId IdType="pubmed">29899036</ArticleId><ArticleId IdType="pmc">6000740</ArticleId><ArticleId IdType="doi">10.1136/bmj.k2179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekirov I, Russell SL, Antunes LC, Finlay BB. Gut microbiota in health and disease. Physiol Rev. 2010;90(3):859&#x2013;904.</Citation><ArticleIdList><ArticleId IdType="pubmed">20664075</ArticleId><ArticleId IdType="doi">10.1152/physrev.00045.2009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, et al. Gut microbiota in patients with irritable bowel syndrome: a systematic review. Gastroenterology. 2019;157(1):97&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940523</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2019.03.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139(6):1844-54.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">20816835</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2010.08.049</ArticleId></ArticleIdList></Reference><Reference><Citation>Manichanh C, Rigottier-Gois L, Bonnaud E, Gloux K, Pelletier E, Frangeul L, et al. Reduced diversity of faecal microbiota in Crohn&#x2019;s disease revealed by a metagenomic approach. Gut. 2006;55(2):205&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">16188921</ArticleId><ArticleId IdType="pmc">1856500</ArticleId><ArticleId IdType="doi">10.1136/gut.2005.073817</ArticleId></ArticleIdList></Reference><Reference><Citation>Avuthu N, Guda C. Meta-analysis of altered gut microbiota reveals microbial and metabolic biomarkers for colorectal cancer. Microbiol Spectr. 2022;10(4): e0001322.</Citation><ArticleIdList><ArticleId IdType="pubmed">35766483</ArticleId><ArticleId IdType="doi">10.1128/spectrum.00013-22</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Lau HC, Liu Y, Kang X, Wang Y, Ting NL, et al. Altered mycobiota signatures and enriched pathogenic Aspergillus rambellii are associated with colorectal cancer based on multicohort fecal metagenomic analyses. Gastroenterology. 2022;163(4):908&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">35724733</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2022.06.038</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam MZ, Tran M, Xu T, Tierney BT, Patel C, Kostic AD. Reproducible and opposing gut microbiome signatures distinguish autoimmune diseases and cancers: a systematic review and meta-analysis. Microbiome. 2022;10(1):218.</Citation><ArticleIdList><ArticleId IdType="pubmed">36482486</ArticleId><ArticleId IdType="pmc">9733034</ArticleId><ArticleId IdType="doi">10.1186/s40168-022-01373-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A, Marrone G, Di Daniele F, Ottaviani E, Wilson Jones G, Bernini R, et al. Impact of gut microbiota composition on onset and progression of chronic non-communicable diseases. Nutrients. 2019;11(5):1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">31091761</ArticleId><ArticleId IdType="pmc">6567014</ArticleId><ArticleId IdType="doi">10.3390/nu11051073</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19043404</ArticleId><ArticleId IdType="doi">10.1038/nature07540</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambeth SM, Carson T, Lowe J, Ramaraj T, Leff JW, Luo L, et al. Composition, diversity and abundance of gut microbiome in prediabetes and type 2 diabetes. J Diabetes Obes. 2015;2(3):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">26756039</ArticleId><ArticleId IdType="pmc">4705851</ArticleId></ArticleIdList></Reference><Reference><Citation>Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson&#x2019;s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis. 2021;7(1):27.</Citation><ArticleIdList><ArticleId IdType="pubmed">33692356</ArticleId><ArticleId IdType="pmc">7946946</ArticleId><ArticleId IdType="doi">10.1038/s41531-021-00156-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Hugon P, Dufour JC, Colson P, Fournier PE, Sallah K, Raoult D. A comprehensive repertoire of prokaryotic species identified in human beings. Lancet Infect Dis. 2015;15(10):1211&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26311042</ArticleId><ArticleId IdType="doi">10.1016/S1473-3099(15)00293-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder BO, Backhed F. Signals from the gut microbiota to distant organs in physiology and disease. Nat Med. 2016;22(10):1079&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">27711063</ArticleId><ArticleId IdType="doi">10.1038/nm.4185</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, Contreras M, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22699611</ArticleId><ArticleId IdType="pmc">3376388</ArticleId><ArticleId IdType="doi">10.1038/nature11053</ArticleId></ArticleIdList></Reference><Reference><Citation>Deschasaux M, Bouter KE, Prodan A, Levin E, Groen AK, Herrema H, et al. Depicting the composition of gut microbiota in a population with varied ethnic origins but shared geography. Nat Med. 2018;24(10):1526&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150717</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0160-1</ArticleId></ArticleIdList></Reference><Reference><Citation>He Y, Wu W, Zheng HM, Li P, McDonald D, Sheng HF, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018;24(10):1532&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30150716</ArticleId><ArticleId IdType="doi">10.1038/s41591-018-0164-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, van Sinderen D, O&#x2019;Toole PW, Stanton C. Feeding the microbiota: transducer of nutrient signals for the host. Gut. 2017;66(9):1709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28663354</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2017-313872</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghosh TS, Rampelli S, Jeffery IB, Santoro A, Neto M, Capri M, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut. 2020;69(7):1218&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pubmed">32066625</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319654</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques TM, Wall R, Ross RP, Fitzgerald GF, Ryan CA, Stanton C. Programming infant gut microbiota: influence of dietary and environmental factors. Curr Opin Biotechnol. 2010;21(2):149&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">20434324</ArticleId><ArticleId IdType="doi">10.1016/j.copbio.2010.03.020</ArticleId></ArticleIdList></Reference><Reference><Citation>Dominguez-Bello MG, Costello EK, Contreras M, Magris M, Hidalgo G, Fierer N, et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20566857</ArticleId><ArticleId IdType="pmc">2900693</ArticleId><ArticleId IdType="doi">10.1073/pnas.1002601107</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuire MK, McGuire MA. Human milk: mother nature&#x2019;s prototypical probiotic food? Adv Nutr. 2015;6(1):112&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25593150</ArticleId><ArticleId IdType="pmc">4288270</ArticleId><ArticleId IdType="doi">10.3945/an.114.007435</ArticleId></ArticleIdList></Reference><Reference><Citation>Vangay P, Ward T, Gerber JS, Knights D. Antibiotics, pediatric dysbiosis, and disease. Cell Host Microbe. 2015;17(5):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">25974298</ArticleId><ArticleId IdType="pmc">5555213</ArticleId><ArticleId IdType="doi">10.1016/j.chom.2015.04.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothschild D, Weissbrod O, Barkan E, Kurilshikov A, Korem T, Zeevi D, et al. Environment dominates over host genetics in shaping human gut microbiota. Nature. 2018;555(7695):210&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">29489753</ArticleId><ArticleId IdType="doi">10.1038/nature25973</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke SF, Murphy EF, O&#x2019;Sullivan O, Lucey AJ, Humphreys M, Hogan A, et al. Exercise and associated dietary extremes impact on gut microbial diversity. Gut. 2014;63(12):1913&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">25021423</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2013-306541</ArticleId></ArticleIdList></Reference><Reference><Citation>Engen PA, Green SJ, Voigt RM, Forsyth CB, Keshavarzian A. The gastrointestinal microbiome: alcohol effects on the composition of intestinal microbiota. Alcohol Res. 2015;37(2):223&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">26695747</ArticleId><ArticleId IdType="pmc">4590619</ArticleId></ArticleIdList></Reference><Reference><Citation>Antinozzi M, Giffi M, Sini N, Galle F, Valeriani F, De Vito C, et al. Cigarette smoking and human gut microbiota in healthy adults: a systematic review. Biomedicines. 2022;10(2):510.</Citation><ArticleIdList><ArticleId IdType="pubmed">35203720</ArticleId><ArticleId IdType="pmc">8962244</ArticleId><ArticleId IdType="doi">10.3390/biomedicines10020510</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S, Schlaeppi K, van der Heijden MGA. Keystone taxa as drivers of microbiome structure and functioning. Nat Rev Microbiol. 2018;16(9):567&#x2013;76.</Citation><ArticleIdList><ArticleId IdType="pubmed">29789680</ArticleId><ArticleId IdType="doi">10.1038/s41579-018-0024-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Frost G, Sleeth ML, Sahuri-Arisoylu M, Lizarbe B, Cerdan S, Brody L, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611.</Citation><ArticleIdList><ArticleId IdType="pubmed">24781306</ArticleId><ArticleId IdType="doi">10.1038/ncomms4611</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vadder F, Kovatcheva-Datchary P, Goncalves D, Vinera J, Zitoun C, Duchampt A, et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell. 2014;156(1&#x2013;2):84&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">24412651</ArticleId><ArticleId IdType="doi">10.1016/j.cell.2013.12.016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, Kosinski JR, et al. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE. 2012;7(4): e35240.</Citation><ArticleIdList><ArticleId IdType="pubmed">22506074</ArticleId><ArticleId IdType="pmc">3323649</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0035240</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Zhang F, Ding X, Wu G, Lam YY, Wang X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes. Science. 2018;359(6380):1151&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29590046</ArticleId><ArticleId IdType="doi">10.1126/science.aao5774</ArticleId></ArticleIdList></Reference><Reference><Citation>Long SL, Gahan CGM, Joyce SA. Interactions between gut bacteria and bile in health and disease. Mol Aspects Med. 2017;56:54&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">28602676</ArticleId><ArticleId IdType="doi">10.1016/j.mam.2017.06.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Yang W, Chen Y, Huang F, Lu L, Lin C, et al. A Clostridia-rich microbiota enhances bile acid excretion in diarrhea-predominant irritable bowel syndrome. J Clin Invest. 2020;130(1):438&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">31815740</ArticleId><ArticleId IdType="doi">10.1172/JCI130976</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">23614584</ArticleId><ArticleId IdType="pmc">3701945</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1109400</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan F, Hill C. Language, numeracy and logic in microbiome science. Nat Rev Gastroenterol Hepatol. 2019;16(7):387&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">31168062</ArticleId><ArticleId IdType="doi">10.1038/s41575-019-0163-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei S, Bahl MI, Baunwall SMD, Hvas CL, Licht TR. Determining gut microbial dysbiosis: a review of applied indexes for assessment of intestinal microbiota imbalances. Appl Environ Microbiol. 2021;87(11):e00395-e421.</Citation><ArticleIdList><ArticleId IdType="pubmed">33741632</ArticleId><ArticleId IdType="pmc">8208139</ArticleId><ArticleId IdType="doi">10.1128/AEM.00395-21</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Alammar N, Singh R, Nanavati J, Song Y, Chaudhary R, et al. Gut microbial dysbiosis in the irritable bowel syndrome: a systematic review and meta-analysis of case-control studies. J Acad Nutr Diet. 2020;120(4):565&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">31473156</ArticleId><ArticleId IdType="doi">10.1016/j.jand.2019.05.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, et al. Diversity of the human intestinal microbial flora. Science. 2005;308(5728):1635&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15831718</ArticleId><ArticleId IdType="pmc">1395357</ArticleId><ArticleId IdType="doi">10.1126/science.1110591</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol. 2002;68(7):3401&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12089021</ArticleId><ArticleId IdType="pmc">126800</ArticleId><ArticleId IdType="doi">10.1128/AEM.68.7.3401-3407.2002</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll IM, Ringel-Kulka T, Keku TO, Chang YH, Packey CD, Sartor RB, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2011;301(5):G799-807.</Citation><ArticleIdList><ArticleId IdType="pubmed">21737778</ArticleId><ArticleId IdType="pmc">3220325</ArticleId><ArticleId IdType="doi">10.1152/ajpgi.00154.2011</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel I, Sundin J, Fuentes S, Repsilber D, de Vos WM, Brummer RJ. The relationship between faecal-associated and mucosal-associated microbiota in irritable bowel syndrome patients and healthy subjects. Aliment Pharmacol Ther. 2015;42(10):1211&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">26376728</ArticleId><ArticleId IdType="doi">10.1111/apt.13399</ArticleId></ArticleIdList></Reference><Reference><Citation>Posserud I, Stotzer PO, Bj&#xf6;rnsson ES, Abrahamsson H, Simr&#xe9;n M. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56(6):802&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17148502</ArticleId><ArticleId IdType="doi">10.1136/gut.2006.108712</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E, Tang J, Pyleris E, Pistiki A, Barbatzas C, Brown J, et al. Molecular assessment of differences in the duodenal microbiome in subjects with irritable bowel syndrome. Scand J Gastroenterol. 2015;50(9):1076&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="pubmed">25865706</ArticleId><ArticleId IdType="doi">10.3109/00365521.2015.1027261</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, Koussoulas V, Barbatzas C, Pimentel M. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57(5):1321&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262197</ArticleId><ArticleId IdType="doi">10.1007/s10620-012-2033-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Villanueva-Millan MJ, Leite G, Wang J, Morales W, Parodi G, Pimentel ML, et al. Methanogens and hydrogen sulfide producing bacteria guide distinct gut microbe profiles and irritable bowel syndrome subtypes. Am J Gastroenterol. 2022;117(12):2055&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">36114762</ArticleId><ArticleId IdType="pmc">9722381</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000001997</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahakian AB, Jee SR, Pimentel M. Methane and the gastrointestinal tract. Dig Dis Sci. 2010;55(8):2135&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">19830557</ArticleId><ArticleId IdType="doi">10.1007/s10620-009-1012-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chang C, Chua KS, Mirocha J, DiBaise J, Rao S, et al. Antibiotic treatment of constipation-predominant irritable bowel syndrome. Dig Dis Sci. 2014;59(6):1278&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24788320</ArticleId><ArticleId IdType="doi">10.1007/s10620-014-3157-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegazi FZ, Abo-Elnaga IG. Degradation of organic acids by dairy lactic acid bacteria. Zentralbl Bakteriol Naturwiss. 1980;135(3):212&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">6775434</ArticleId></ArticleIdList></Reference><Reference><Citation>Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S. Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22(5):512&#x2013;9 (e114&#x2013;5).</Citation><ArticleIdList><ArticleId IdType="pubmed">19903265</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatty JK, Bhargava A, Buret AG. Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection. World J Gastroenterol. 2014;20(14):3976&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">24744587</ArticleId><ArticleId IdType="pmc">3983453</ArticleId><ArticleId IdType="doi">10.3748/wjg.v20.i14.3976</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM, Murray JA, Pimentel M. AGA clinical practice update on small intestinal bacterial overgrowth: expert review. Gastroenterology. 2020;159(4):1526&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">32679220</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2020.06.090</ArticleId></ArticleIdList></Reference><Reference><Citation>Vervier K, Moss S, Kumar N, Adoum A, Barne M, Browne H, et al. Two microbiota subtypes identified in irritable bowel syndrome with distinct responses to the low FODMAP diet. Gut. 2022;71(9):1821&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">34810234</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2021-325177</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Salhy M, Hatlebakk JG, Gilja OH, Brathen Kristoffersen A, Hausken T. Efficacy of faecal microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind, placebo-controlled study. Gut. 2020;69(5):859&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31852769</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2019-319630</ArticleId></ArticleIdList></Reference><Reference><Citation>Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, et al. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Gut. 2018;67(12):2107&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">29980607</ArticleId><ArticleId IdType="doi">10.1136/gutjnl-2018-316434</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmermann P, Curtis N. The effect of antibiotics on the composition of the intestinal microbiota: a systematic review. J Infect. 2019;79(6):471&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">31629863</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2019.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Krogsgaard LR, Engsbro AL, Bytzer P. Antibiotics: a risk factor for irritable bowel syndrome in a population-based cohort. Scand J Gastroenterol. 2018;53(9):1027&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">30189148</ArticleId><ArticleId IdType="doi">10.1080/00365521.2018.1500638</ArticleId></ArticleIdList></Reference><Reference><Citation>Paula H, Grover M, Halder SL, Locke GR 3rd, Schleck CD, Zinsmeister AR, et al. Non-enteric infections, antibiotic use, and risk of development of functional gastrointestinal disorders. Neurogastroenterol Motil. 2015;27(11):1580&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">26303310</ArticleId><ArticleId IdType="pmc">4624515</ArticleId><ArticleId IdType="doi">10.1111/nmo.12655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003;98(2):412&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591062</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoshal UC, Srivastava D, Misra A, Ghoshal U. A proof-of-concept study showing antibiotics to be more effective in irritable bowel syndrome with than without small-intestinal bacterial overgrowth: a randomized, double-blind, placebo-controlled trial. Eur J Gastroenterol Hepatol. 2016;28(3):281&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26731696</ArticleId><ArticleId IdType="doi">10.1097/MEG.0000000000000557</ArticleId></ArticleIdList></Reference><Reference><Citation>Lembo A, Zakko S, Ferreira N, Ringel Y, Bortey E, Courtney K, et al. Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterology. 2008;134(Suppl. 1):A545.</Citation></Reference><Reference><Citation>Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol. 2006;101(2):326&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">16454838</ArticleId><ArticleId IdType="doi">10.1111/j.1572-0241.2006.00458.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006;145(8):557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">17043337</ArticleId><ArticleId IdType="doi">10.7326/0003-4819-145-8-200610170-00004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford AC, Harris LA, Lacy BE, Quigley EMM, Moayyedi P. Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome. Aliment Pharmacol Ther. 2018;48(10):1044&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">30294792</ArticleId><ArticleId IdType="doi">10.1111/apt.15001</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah E, Kim S, Chong K, Lembo A, Pimentel M. Evaluation of harm in the pharmacotherapy of irritable bowel syndrome. Am J Med. 2012;125(4):381&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">22444104</ArticleId><ArticleId IdType="doi">10.1016/j.amjmed.2011.08.026</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezaie A, Heimanson Z, McCallum R, Pimentel M. Lactulose breath testing as a predictor of response to rifaximin in patients with irritable bowel syndrome with diarrhea. Am J Gastroenterol. 2019;114(12):1886&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">31688023</ArticleId><ArticleId IdType="pmc">6903366</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000000444</ArticleId></ArticleIdList></Reference><Reference><Citation>Pimentel M. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea. Aliment Pharmacol Ther. 2016;43(Suppl 1):37&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">26618924</ArticleId><ArticleId IdType="doi">10.1111/apt.13437</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Agricultural Organisation of the United Nations (FAO) and World Health Organization (WHO). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. https://www.fao.org/3/y6398e/y6398e.pdf . Accessed 23 Feb 2023.</Citation></Reference><Reference><Citation>Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">24912386</ArticleId><ArticleId IdType="doi">10.1038/nrgastro.2014.66</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EM. Probiotics in irritable bowel syndrome: the science and the evidence. J Clin Gastroenterol. 2015;49(Suppl. 1):S60&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">26447967</ArticleId><ArticleId IdType="doi">10.1097/MCG.0000000000000348</ArticleId></ArticleIdList></Reference><Reference><Citation>Ringel-Kulka T, Goldsmith JR, Carroll IM, Barros SP, Palsson O, Jobin C, et al. Lactobacillus acidophilus NCFM affects colonic mucosal opioid receptor expression in patients with functional abdominal pain: a randomised clinical study. Aliment Pharmacol Ther. 2014;40(2):200&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24853043</ArticleId><ArticleId IdType="pmc">4613798</ArticleId><ArticleId IdType="doi">10.1111/apt.12800</ArticleId></ArticleIdList></Reference><Reference><Citation>Rousseaux C, Thuru X, Gelot A, Barnich N, Neut C, Dubuquoy L, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med. 2007;13(1):35&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17159985</ArticleId><ArticleId IdType="doi">10.1038/nm1521</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128(3):541&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">15765388</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2004.11.050</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, et al. Probiotic Bifidobacterium longum NCC3001 reduces depression scores and alters brain activity: a pilot study in patients with irritable bowel syndrome. Gastroenterology. 2017;153(2):448-59.e8.</Citation><ArticleIdList><ArticleId IdType="pubmed">28483500</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2017.05.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Andresen V, Gschossmann J, Layer P. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial. Lancet Gastroenterol Hepatol. 2020;5(7):658&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">32277872</ArticleId><ArticleId IdType="doi">10.1016/S2468-1253(20)30056-X</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai T, Xu Z, Xia P, Feng Y, Liu B, Liu H, et al. The short-term efficacy of Bifidobacterium quadruple viable tablet in patients with diarrhea-predominant irritable bowel syndrome: potentially mediated by metabolism rather than diversity regulation. Am J Gastroenterol. 2022.</Citation></Reference><Reference><Citation>Quigley EMM, Markinson L, Stevenson A, Treasure FP, Lacy BE. Randomised clinical trial: efficacy and safety of the live biotherapeutic product MRx1234 in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2023;57(1):81&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">36369645</ArticleId><ArticleId IdType="doi">10.1111/apt.17310</ArticleId></ArticleIdList></Reference><Reference><Citation>Irvine EJ, Tack J, Crowell MD, Gwee KA, Ke M, Schmulson MJ, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2016;150(6):1469-80.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">27147123</ArticleId><ArticleId IdType="doi">10.1053/j.gastro.2016.02.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Quigley EMM. Clinical trials of probiotics in patients with irritable bowel syndrome: some points to consider. J Neurogastroenterol Motil. 2022;28(2):204&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">35189598</ArticleId><ArticleId IdType="pmc">8978119</ArticleId><ArticleId IdType="doi">10.5056/jnm22012</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1(8390):1311&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">6145023</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(84)91816-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch&#x2019;s postulates for pyloric Campylobacter. Med J Aust. 1985;142(8):436&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">3982345</ArticleId><ArticleId IdType="doi">10.5694/j.1326-5377.1985.tb113443.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Falony G, Joossens M, Vieira-Silva S, Wang J, Darzi Y, Faust K, et al. Population-level analysis of gut microbiome variation. Science. 2016;352(6285):560&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126039</ArticleId><ArticleId IdType="doi">10.1126/science.aad3503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhernakova A, Kurilshikov A, Bonder MJ, Tigchelaar EF, Schirmer M, Vatanen T, et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science. 2016;352(6285):565&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27126040</ArticleId><ArticleId IdType="pmc">5240844</ArticleId><ArticleId IdType="doi">10.1126/science.aad3369</ArticleId></ArticleIdList></Reference><Reference><Citation>Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, et al. Enterotypes of the human gut microbiome. Nature. 2011;473(7346):174&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">21508958</ArticleId><ArticleId IdType="pmc">3728647</ArticleId><ArticleId IdType="doi">10.1038/nature09944</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>